Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30008495HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059013HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059014HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059015HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059016HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059017HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059018HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059019HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059020HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059021HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TCGA Plot Options
Drug Information
GenePIK3CA
DrugBank IDDB00171
Drug NameATP
Target IDBE0002379
UniProt IDP42336
Regulation Type
PubMed IDs18754654
CitationsFolkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ: The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . J Med Chem. 2008 Sep 25;51(18):5522-32. doi: 10.1021/jm800295d.
GroupsInvestigational; Nutraceutical
Direct ClassificationPurine ribonucleoside triphosphates
SMILESNC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
PathwaysGlycerolipid Metabolism; Fatty Acid Metabolism; Pamidronate Action Pathway; Simvastatin Action Pathway; Citric Acid Cycle; Glutamate Metabolism; Argininosuccinic Aciduria; Gluconeogenesis; Betaine Metabolism; Butyrate Metabolism; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Rosuvastatin Action Pathway; Propanoate Metabolism; Pentose Phosphate Pathway; Pyruvate Metabolism; Inositol Metabolism; Zoledronate Action Pathway; Glycine and Serine Metabolism; Selenoamino Acid Metabolism; Thiamine Metabolism; Pyrimidine Metabolism; Carbamoyl Phosphate Synthetase Deficiency; Ammonia Recycling; Histidine Metabolism; Pravastatin Action Pathway; Arginine and Proline Metabolism; Starch and Sucrose Metabolism; Purine Metabolism; Fluvastatin Action Pathway; Galactose Metabolism
PharmGKBPA164743471
ChEMBLCHEMBL14249